CSL (OTCMKTS:CSLLY) Rating Lowered to "Strong Sell" at Zacks Research

Key Points

• CSL has been downgraded from a "hold" rating to a "strong sell" rating by Zacks Research as of Monday.
• The company's stock opened at $67.04, with a fifty-two week range from $64.68 to $101.44.
• CSL Limited is heavily involved in the research, development, and distribution of biopharmaceuticals and vaccines globally, operating through various segments including CSL Behring and CSL Seqirus.

Zacks Research downgraded shares of CSL (OTCMKTS:CSLLY - Free Report) from a hold rating to a strong sell rating in a report issued on Monday morning,Zacks.com reports.

CSL Stock Down 0.7%

CSLLY stock traded down $0.48 during trading on Monday, hitting $65.38. 202,548 shares of the stock traded hands, compared to its average volume of 173,681. The company has a current ratio of 2.46, a quick ratio of 1.12 and a debt-to-equity ratio of 0.50. CSL has a one year low of $64.68 and a one year high of $101.44. The company has a 50 day simple moving average of $77.79 and a 200 day simple moving average of $78.34.

CSL Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.